0.7677
price up icon5.64%   0.041
after-market After Hours: .76 -0.0077 -1.00%
loading
Coherus Oncology Inc stock is traded at $0.7677, with a volume of 1.42M. It is up +5.64% in the last 24 hours and up +1.53% over the past month. Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
See More
Previous Close:
$0.7267
Open:
$0.7315
24h Volume:
1.42M
Relative Volume:
0.87
Market Cap:
$93.31M
Revenue:
$257.24M
Net Income/Loss:
$-237.89M
P/E Ratio:
-0.2953
EPS:
-2.6
Net Cash Flow:
$-175.17M
1W Performance:
+1.28%
1M Performance:
+1.53%
6M Performance:
-47.78%
1Y Performance:
-52.90%
1-Day Range:
Value
$0.7315
$0.7695
1-Week Range:
Value
$0.71
$0.77
52-Week Range:
Value
$0.6603
$2.43

Coherus Oncology Inc Stock (CHRS) Company Profile

Name
Name
Coherus Oncology Inc
Name
Phone
(650) 649-3530
Name
Address
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Name
Employee
221
Name
Twitter
@coherus_bio
Name
Next Earnings Date
2025-03-10
Name
Latest SEC Filings
Name
CHRS's Discussions on Twitter

Compare CHRS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CHRS
Coherus Oncology Inc
0.7677 93.31M 257.24M -237.89M -175.17M -2.60
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.27 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.27 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.00 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
568.06 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
266.80 28.51B 3.81B -644.79M -669.77M -6.24

Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-16-24 Downgrade UBS Buy → Neutral
Nov-17-23 Initiated Robert W. Baird Outperform
Nov-08-23 Downgrade Maxim Group Buy → Hold
Jul-24-23 Initiated Citigroup Buy
May-01-23 Initiated Truist Buy
Mar-28-23 Upgrade UBS Neutral → Buy
Jun-14-22 Initiated UBS Neutral
Mar-07-22 Downgrade JP Morgan Overweight → Neutral
Jul-16-20 Initiated BofA Securities Neutral
Apr-17-20 Initiated SunTrust Buy
Aug-13-19 Initiated Mizuho Buy
Aug-02-19 Reiterated H.C. Wainwright Buy
Aug-02-19 Reiterated Maxim Group Buy
Jun-11-19 Initiated Barclays Overweight
May-07-19 Initiated H.C. Wainwright Buy
Aug-28-18 Initiated H.C. Wainwright Buy
Mar-09-18 Reiterated Maxim Group Buy
Aug-08-17 Reiterated JP Morgan Overweight
Jun-13-17 Reiterated Maxim Group Buy
May-05-17 Initiated BMO Capital Markets Outperform
Oct-19-16 Initiated Robert W. Baird Outperform
Sep-07-16 Initiated Maxim Group Buy
Jul-27-16 Initiated Citigroup Buy
Jan-20-16 Initiated Credit Suisse Outperform
View All

Coherus Oncology Inc Stock (CHRS) Latest News

pulisher
Jun 13, 2025

Coherus Oncology reports annual meeting results By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 13, 2025

Coherus Oncology reports annual meeting results - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Coherus Biosciences Holds Virtual Annual Stockholder Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 06, 2025

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory - Insider Monkey

Jun 06, 2025
pulisher
Jun 04, 2025

Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada

Jun 04, 2025
pulisher
May 31, 2025

Genocea Biosciences (NASDAQ:GNCAQ) vs. Coherus BioSciences (NASDAQ:CHRS) Critical Survey - Defense World

May 31, 2025
pulisher
May 30, 2025

Coherus Oncology (CHRS) Shifts Focus with New Name and Innovativ - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Coherus Biosciences Rebrands to Coherus Oncology - TipRanks

May 30, 2025
pulisher
May 30, 2025

Coherus Completes Strategic Transformation to Coherus Oncology, - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | CHRS Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Coherus Completes Strategic Transformation To Coherus Oncology - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Coherus Completes Strategic Transformation to Coherus - GlobeNewswire

May 30, 2025
pulisher
May 30, 2025

Coherus Makes Bold Strategic Shift: Rebrands as Cancer-Focused Powerhouse with 3 Novel Immunotherapies - Stock Titan

May 30, 2025
pulisher
May 30, 2025

Coherus Oncology (CHRS) Shifts Focus with New Name and Innovative Therapies | CHRS Stock News - GuruFocus

May 30, 2025
pulisher
May 28, 2025

First patient dosed in STORM-Coherus cancer alliance - Business Weekly

May 28, 2025
pulisher
May 27, 2025

Coherus BioSciences at 6th Annual Oncology Summit: Strategic Shift to Innovation - Investing.com Canada

May 27, 2025
pulisher
May 27, 2025

Coherus BioSciences, Inc. Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI®? (toripalimab-Ttzi) - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Coherus BioSciences (CHRS) Engages in New Cancer Treatment Colla - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Coherus BioSciences (CHRS) Engages in New Cancer Treatment Collaboration | CHRS Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Coherus Announces Clinical Collaboration with STORM Therapeutics - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) | CHRS Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Coherus Announces Clinical Collaboration with STORM - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

Breakthrough Cancer Trial Launches: LOQTORZI Combination Study Targets 4 Major Cancer Types - Stock Titan

May 27, 2025
pulisher
May 22, 2025

Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles By Investing.com - Investing.com Canada

May 22, 2025
pulisher
May 22, 2025

Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles - Investing.com

May 22, 2025
pulisher
May 20, 2025

StockNews.com Downgrades Coherus BioSciences (NASDAQ:CHRS) to Sell - Defense World

May 20, 2025
pulisher
May 20, 2025

The Manufacturers Life Insurance Company Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World

May 20, 2025
pulisher
May 18, 2025

Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 32% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st

May 18, 2025
pulisher
May 15, 2025

Coherus BioSciences Earnings Call Highlights Transition and Growth - TipRanks

May 15, 2025
pulisher
May 15, 2025

Some Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Just Made A Major Cut To Next Year's Estimates - simplywall.st

May 15, 2025
pulisher
May 14, 2025

Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 14, 2025
pulisher
May 14, 2025

Coherus BioSciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

May 14, 2025
pulisher
May 13, 2025

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | CHRS Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Coherus BioSciences Q1 2025 Earnings Call Transcript - MarketBeat

May 13, 2025
pulisher
May 13, 2025

Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Wells Fargo & Company MN Has $85,000 Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World

May 13, 2025
pulisher
May 13, 2025

Coherus BioSciences: Q1 2025 Financial Highlights and Strategic Shift - TipRanks

May 13, 2025
pulisher
May 12, 2025

Coherus BioSciences (CHRS) Focuses on Oncology After Divestitures - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Earnings call transcript: Coherus BioSciences sees flat revenue, stock slides post-Q1 2025 - Investing.com Nigeria

May 12, 2025
pulisher
May 12, 2025

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - ADVFN

May 12, 2025
pulisher
May 12, 2025

Coherus BioSciences Inc Reports Q1 2025 Results: EPS of $(0.41) Misses Estimate, Revenue at $7.6 Million Falls Short - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Coherus BioSciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Coherus BioSciences (CHRS) Reports Q1 Revenue Surge, Faces Share Decline - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Coherus BioSciences: Q1 Earnings Snapshot - San Antonio Express-News

May 12, 2025
pulisher
May 12, 2025

Coherus BioSciences Reports Q1 2025 Financial Results and Advances Oncology Portfolio with CHS-114 and LOQTORZI Developments - Nasdaq

May 12, 2025

Coherus Oncology Inc Stock (CHRS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.74
price up icon 0.29%
$36.14
price up icon 2.09%
$20.92
price up icon 2.60%
$105.90
price up icon 0.46%
$105.09
price up icon 2.02%
biotechnology ONC
$266.80
price up icon 3.61%
Cap:     |  Volume (24h):